Bruker to acquire NanoString business

Bruker this week announced it entered into a definitive acquisition agreement with NanoString Technologies.

Under the agreement’s terms, Bruker will substantially acquire all of the assets and rights associated with NanoString’s business for approximately $392.6 million in cash and the assumption of certain liabilities.

The transaction was approved under a court-supervised Chapter 11 sale process pursuant to Section 363 of the U.S. Bankruptcy Code. It is expected to close in the second quarter of 2024 and is subject to customary closing conditions.

NanoString develops life science tools for discovery and translational expression analysis. Its revenues were $168 million in 2023.

“The acquisition of NanoString will add gene expression profiling and spatial transcriptomics solutions and products to Bruker’s spatial biology portfolio,” Mark Munch, President of Bruker Nano Group, said in a news release. “NanoString’s innovative platforms ar…

Read more
  • 0

Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…
Read more
  • 0